Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
Returns on capital
Satellos Bioscience Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-91.3%
avg -21.5%
ROIC
-97.1%
avg -101.1%
ROA
-79.5%
avg -176.1%
Analysis
ROA is currently the strongest return metric at -79.5% versus its period average of -176.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Francis Gleeson | Co-Founder, Chief Executive Officer, President & Director | CAD 922.14K | 71 | — | — |
Philip Lambert | Chief Scientific Officer | CAD 805.11K | 57 | — | — |
Elizabeth Williams | Chief Financial Officer & Corporate Secretary | CAD 681.36K | 48 | — | — |
Wildon Farwell | Chief Medical Officer | CAD 406.69K | 50 | — | — |
Warren Whitehead | Head of Corporate Strategy | CAD 313.54K | 74 | — | — |
Michael A. Rudnicki | Co-Founder & Chief Discovery Officer | CAD 120K | 64 | — | — |
Michael Liggett | Strategic Advisor | CAD 44.48K | 66 | — | — |
Ryan Mitchell | Senior VP & Head of Corporate Development | — | — | — | — |
J. Robert Hall | Senior Vice President of Finance & Administration | — | — | — | — |
Antoinette Paone | Chief Development Officer & Head of Regulatory Affairs | — | 47 | — | — |
Desiree Chan | Chief of Staff | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Satellos Bioscience Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MSCL.TO's management, answered from reported figures.
Who manages MSCL.TO?
Satellos Bioscience Inc. (MSCL.TO) lists 11 active executives. The top listed executive is Michael A. Rudnicki, Co-Founder & Chief Discovery Officer.
Continue the stock analysis
Jump to another research area for this company.